Why the study?
Does interrupting long-term anticoagulant treatment for bleeding increase the risk of rebound thromboembolic complications compared to interruption for other reasons in patients on long-term anticoagulation?
Does interrupting long-term anticoagulant treatment for bleeding increase the risk of rebound thromboembolic complications compared to interruption for other reasons in patients on long-term anticoagulation?
Interrupting long-term anticoagulation due to bleeding is associated with a significantly higher risk of rebound thromboembolic complications compared to interruption for other reasons.
Answers are grounded in this paper and cite their sources.
Interruption for bleeding warrants caution pending confirmation; leaves open optimal strategies for short-term anticoagulant holds.
From a series of 310 patients on long-term anticoagulant treatment for various conditions 136 instances were collected in which treatment was interrupted. This was because of bleeding in 45 instances, for permanent reasons in 53 instances, and for temporary reasons in 38 instances. Rebound thromboembolic complications were observed significantly more frequently in those who stopped treatment for bleeding. The cause of the rebound effect could not be ascribed to vitamin K 1 administration, transfusions, or overt ischemic effects from blood loss although the latter might have been contributory to a small extent. The observations suggested a hypercoagulable state induced directly in some obscure way as a result of the bleeding. Interruption of treatment for reasons other than bleeding was not associated with early complications. The risk of interruption of treatment for short periods was relatively small (three nonfatal complications in 38 instances). In those who stopped permanently, complications were most often seen after 2 months.
No takes yet. Share an insight, caveat, or question.
Sise et al. (1961) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: